Sitagliptin Significantly Decreases the Ratio of Glycated Albumin to HbA1c in Patients with Type 2 Diabetes MellitusShogo Kurebayashi1, Takashi Motomura2, Kayoko Goya1, Makoto Nakao3, Kunihiko Hashimoto4, Yasuhiko Morimoto4, Tetsuhiro Kitamura5, Atsunori Fukuhara5, Bunzo Sato6, Soji Kasayama6, Iichiro Shimomura5, Masafumi Koga7* and Michio Otsuki5
- *Corresponding Author:
- Masafumi Koga
Department of Internal Medicine, Kawanishi City Hospital
5-21-1 Higashi-Uneno, Kawanishi, Hyogo 666-0195, Japan
E-mail: [email protected]
Received date: February 14, 2014; Accepted date: March 18, 2014; Published date: March 23, 2014
Citation: Kurebayashi S, Motomura T, Goya K, Nakao M, Hashimoto K, et al. (2014) Sitagliptin Significantly Decreases the Ratio of Glycated Albumin to Hba1c in Patients with Type 2 Diabetes Mellitus. J Diabetes Metab 5:343. doi: 10.4172/2155-6156.1000343
Copyright: © 2014 Kurebayashi S, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Background: Since glycated albumin (GA) is a glycemic control marker which reflects more postprandial plasma glucose (PPPG) and/or glycemic excursions than HbA1c, the GA/HbA1c ratio is a useful indicator for PPPG and/or glycemic excursions. In this study, we investigated the clinical significance of the GA/HbA1c ratio by administration of sitagliptin, a dipeptidyl peptidase-4 (DPP-4) inhibitor, in patients with type 2 diabetes mellitus.
Methods: Sitagliptin (50 mg/day) was administered for 24 weeks to 69 patients with type 2 diabetes mellitus with stable glycemic control.
Results: With sitagliptin administration, both HbA1c and GA significantly decreased from baseline to the periods of week 4 and week 24. The GA/HbA1c ratio also significantly decreased (baseline 2.72 ± 0.42 vs. 24 weeks 2.60 ± 0.38, P<0.0001). The change in the GA/HbA1c ratio with the sitagliptin administration for 24 weeks was inversely correlated with baseline GA (R=-0.425, P<0.001) and baseline GA/HbA1c ratio (R=-0.354, P=0.003), but not with baseline HbA1c (R=-0.222, P=0.066). By tertile analysis based on the baseline GA/HbA1c ratio, the GA/HbA1c ratios were significantly associated with GA (P<0.0001), but not fasting plasma glucose (FPG) and HbA1c. Furthermore, changes in GA (P=0.010), but not FPG and HbA1c, were significantly correlated with the baseline GA/HbA1c ratio.
Conclusions: Sitagliptin significantly decreased the GA/HbA1c ratio and this effect was more pronounced in patients with the higher baseline GA/HbA1c ratio. Our findings suggest that the effect of sitagliptin on the GA/HbA1c ratio might reflect improvement of PPPG levels and/or glycemic excursion.